Reunion Neuroscience
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.
Tech Stack (20 technologies)
Frequently Asked Questions
What technologies does Reunion Neuroscience use?+
Reunion Neuroscience uses 20 technologies including Google Analytics, Google Tag Manager, Modernizr.
What industry is Reunion Neuroscience in?+
Reunion Neuroscience operates in the Biotechnology industry.
Where is Reunion Neuroscience based?+
Reunion Neuroscience is headquartered in Canada.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026